Hoth Therapeutics (NASDAQ:HOTH) Trading Down 7.1%

Hoth Therapeutics, Inc. (NASDAQ:HOTH) shares traded down 7.1% during trading on Monday . The stock traded as low as $1.67 and last traded at $1.71. 201,461 shares were traded during trading, a decline of 80% from the average session volume of 1,014,072 shares. The stock had previously closed at $1.84.

Hoth Therapeutics Stock Down 7.1 %

The firm has a market cap of $5.64 million, a price-to-earnings ratio of -0.27 and a beta of 0.47. The stock has a fifty day moving average price of $2.44 and a 200-day moving average price of $2.32.

Hoth Therapeutics (NASDAQ:HOTH) last released its earnings results on Friday, August 11th. The company reported ($0.57) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in Hoth Therapeutics by 23.2% during the third quarter. Vanguard Group Inc. now owns 942,305 shares of the company’s stock worth $328,000 after acquiring an additional 177,659 shares during the period. Armistice Capital LLC acquired a new position in Hoth Therapeutics during the fourth quarter worth $1,092,000. Virtu Financial LLC grew its holdings in Hoth Therapeutics by 453.2% during the second quarter. Virtu Financial LLC now owns 138,213 shares of the company’s stock worth $58,000 after acquiring an additional 113,229 shares during the period. Renaissance Technologies LLC grew its holdings in Hoth Therapeutics by 77.9% during the second quarter. Renaissance Technologies LLC now owns 157,245 shares of the company’s stock worth $66,000 after acquiring an additional 68,845 shares during the period. Finally, Acadian Asset Management LLC acquired a new position in Hoth Therapeutics during the first quarter worth $80,000. Institutional investors and hedge funds own 2.17% of the company’s stock.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.